Am. Brown et Gf. Gibbons, Insulin inhibits the maturation phase of VLDL assembly via a phosphoinositide 3-kinase-mediated event, ART THROM V, 21(10), 2001, pp. 1656-1661
LY 294002 (80 mu mol/L), an inhibitor of phosphoinositide 3-kinase, was use
d to investigate the involvement of this enzyme in the insulin-mediated reg
ulation of very low density lipoprotein (VLDL) apolipoprotein B (apoB) outp
ut from cultured rat hepatocytes. Newly synthesized apoB was pulse-labeled
with [S-35] methionine and was then allowed to assemble, via an intermediat
e precursor stage, into mature VLDL during subsequent chase periods. Brefel
din A (BFA, 0.2 mug/mL) was used to discriminate between the role of insuli
n in the regulation of the early, compared with the later, events of VLDL a
ssembly, including apoB degradation. Insulin (78 nmol/L), when present duri
ng the pulse-labeling and subsequent chase periods, inhibited the secretion
of apoB-100 and apoB-48 as VLDL by 53% and 56%, respectively. Degradation
of both was concomitantly increased. Secretion of high density lipoprotein
apoB, derived from VLDL precursors, was relatively unaffected under these c
onditions, as was the net synthesis of apoB-100 and apoB-48. The presence o
f BFA during the pulse-labeling period and subsequent chase period prevente
d the maturation of VLDL in the insulin-treated and the non-insulin-treated
cells. BFA was then removed, allowing the maturation of VLDL to proceed. R
emoval of insulin at this stage reversed the overall inhibitory effect of i
nsulin. Furthermore, when insulin remained present during this period, the
simultaneous presence of LY 294002 also reversed the inhibitory effect of i
nsulin on VLDL apoB output and abolished the increase in apoB degradation.
The results suggest that insulin signaling via phosphoinositide 3-kinase in
hibited the maturation phase of VLDL assembly by preventing bulk lipid tran
sfer to a VLDL precursor, thus enhancing the degradation of apoB. There was
no inhibition of the conversion of newly synthesized apoB into the VLDL pr
ecursor form.